Compounds and Compositions for Treating Chemical Warfare Agent-Induced Injuries
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,710,052 | Compounds and Compositions for Treating Chemical Warfare Agent-Induced Injuries In force · High confidence UsedRemaining | Eli Lilly and Company | In force | High confidence | ||
| US 9,260,431 | Compounds and Compositions for Treating Chemical Warfare Agent-Induced Injuries In force · High confidence | Eli Lilly and Company | In force | High confidence | ||
| US 9,980,968 | Compounds and Compositions for Treating Chemical Warfare Agent-Induced Injuries In force · High confidence | Eli Lilly and Company | In force | High confidence | ||
| US 8,318,728 | Compounds and Compositions for Treating Chemical Warfare Agent-Induced Injuries In force · High confidence | Hydra Biosciences, Inc. | In force | High confidence |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Hydra Biosciences, Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.